The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability

Eitemau Tebyg

• The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning
  gan: Bruno, Peter M., et al.
  Cyhoeddwyd: (2020)
• A Deconvolution Protocol for ChIP-Seq Reveals Analogous Enhancer Structures on the Mouse and Human Ribosomal RNA Genes
  gan: Mars, Jean-Clement, et al.
  Cyhoeddwyd: (2017)
• Ribosomal DNA promoter recognition is determined in vivo by cooperation between UBTF1 and SL1 and is compromised in the UBTF-E210K neuroregression syndrome.
  gan: Michel G Tremblay, et al.
  Cyhoeddwyd: (2022-02-01)
• Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
  gan: Haddach, Mustapha, et al.
  Cyhoeddwyd: (2012)
• Impact of RNA polymerase I inhibitor CX-5461 on viral kinase-dependent and -independent cytomegalovirus replication
  gan: Westdorp, Kristen N., et al.
  Cyhoeddwyd: (2018)